Last Updated: November 16, 2026

Investigational Drug Information for Reparixin

« Back to Dashboard


What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 14 clinical trials for Reparixin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and Novartis.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)NovartisPhase 2
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Icahn School of Medicine at Mount SinaiPhase 2
Add-on Reparixin in Adult Patients With ARDSDompé Farmaceutici S.p.APhase 2

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

Reparixin Development Update and Market Projection

Last updated: September 11, 2026

Reparixin is an investigational oral CXCR1/CXCR2 inhibitor developed by Dompé Farmaceutici. It has not received FDA, EMA, or other major-market approval. Its principal clinical opportunities have been inflammatory diseases, pancreatic islet transplantation, and oncology, including breast cancer. The commercial outlook remains speculative because no active late-stage program, registration filing, or confirmed launch timeline is publicly established.

What is the current development status of reparixin?

Reparixin is a small-molecule inhibitor of the chemokine receptors CXCR1 and CXCR2. The target pathway regulates neutrophil recruitment and inflammatory signaling. The compound has been evaluated in oral formulations and in clinical settings where excessive inflammation or tumor-associated neutrophil activity may contribute to disease progression.

The development record includes:

Development area Clinical rationale Development position
Pancreatic islet transplantation Reduce early inflammatory injury and improve graft function Mid-stage clinical investigation
Breast cancer Target CXCR1-positive cancer stem-cell biology and tumor recurrence Phase 2 investigation
Acute inflammatory conditions Reduce neutrophil-mediated tissue injury Early- to mid-stage research
COVID-19-related pulmonary inflammation Limit inflammatory lung injury Clinical investigation reported during the pandemic
Other oncology indications Explore tumor microenvironment and cancer stem-cell mechanisms Preclinical or exploratory

The most commercially relevant program has historically been oncology, particularly triple-negative breast cancer. The transplantation program addresses a smaller specialist market and would require adoption in a highly controlled clinical setting.

What diseases has reparixin been studied in?

Breast cancer

Reparixin has been studied in patients with breast cancer, including patients receiving treatment in the neoadjuvant or metastatic setting. The biological premise is that CXCR1 inhibition may reduce the survival and activity of tumor-initiating cells and alter the tumor microenvironment.

A randomized Phase 2 study evaluated reparixin in combination with chemotherapy in patients with metastatic breast cancer. ClinicalTrials.gov lists reparixin breast cancer studies under Dompé and affiliated investigators.[1] Publicly available development information has not established a statistically validated efficacy profile sufficient to support registration.

The key clinical risks are:

  • Uncertain benefit in biomarker-unselected patients.
  • Difficulty translating cancer-stem-cell biology into durable clinical outcomes.
  • Competition from antibody-drug conjugates, immunotherapies, PARP inhibitors, and newer targeted therapies.
  • The need for a clinically meaningful endpoint, such as overall survival or durable progression-free survival.

Pancreatic islet transplantation

Reparixin has been evaluated as an adjunct in pancreatic islet transplantation. The treatment objective is to reduce inflammatory injury after transplantation and improve graft survival or insulin independence.

This indication has a clear mechanistic rationale, but the addressable population is small. Commercial uptake would depend on:

  • Demonstrated improvement in graft function.
  • Reduced insulin requirements.
  • A favorable infection and immunosuppression profile.
  • Reimbursement for a specialist transplant procedure.
  • Compatibility with current immunosuppressive regimens.

A positive transplant result would likely support a niche product rather than a mass-market medicine.

Acute lung inflammation and COVID-19

CXCR1/CXCR2 blockade was investigated as a way to reduce neutrophil-driven pulmonary inflammation during severe respiratory disease. Reparixin was evaluated during the COVID-19 period, but the public development record has not produced a regulatory approval or a clearly established commercial pathway in this indication.

The COVID-19 opportunity has largely diminished as a standalone market because treatment standards, vaccination, and disease severity patterns have changed. Any future pulmonary indication would need to focus on a defined inflammatory phenotype rather than broad viral infection.

What is the FDA regulatory status of reparixin?

Reparixin is not FDA-approved. It does not have an FDA-approved label, established US commercial price, or approved dosage regimen.

The drug has been studied under investigational protocols. The public record does not show a completed New Drug Application approval or a biologics license application because reparixin is a small molecule. Any future US launch would require:

  1. A completed development program.
  2. Adequate and well-controlled clinical trials.
  3. Manufacturing and quality documentation.
  4. A regulatory filing with the FDA.
  5. Approval of a specific indication, dosage form, and treatment regimen.

Reparixin would use the conventional small-molecule drug pathway rather than the biosimilar pathway. Biosimilar risk is therefore not directly relevant. The principal competitive risks are generic substitution after any future approval and competition from existing branded therapies.

When does reparixin lose exclusivity?

No reliable public launch date or final approval date exists from which to calculate a commercial exclusivity expiration date. Reparixin therefore has no confirmed US regulatory exclusivity end date.

Patent protection must be assessed separately from regulatory exclusivity. Publicly reported patent information for reparixin is less transparent than the Orange Book records for approved drugs. Because reparixin has no FDA-approved product, it is not expected to have an FDA Orange Book listing.

Potential protection could include:

  • Composition-of-matter patents.
  • Salt or polymorph patents.
  • Oral formulation patents.
  • Manufacturing-process patents.
  • Method-of-use patents for inflammatory or oncology indications.
  • Combination-treatment patents.

The commercial value of any remaining patents would depend on claim scope, priority dates, prosecution history, terminal disclaimers, patent-term adjustment, and jurisdiction. A broad early composition patent would be more valuable than a later method-of-use patent limited to a narrow patient population.

What patents protect reparixin?

A complete patent opinion cannot be derived from the drug name alone. Reparixin has been developed across multiple indications and jurisdictions, and patent families may identify the compound through chemical names, code numbers, salts, formulations, or therapeutic uses rather than the word "reparixin."

The relevant diligence questions are:

Patent category Business relevance
Core compound claims Determines the principal period of generic exclusion
Crystalline or salt-form claims May protect commercial drug substance or stability
Formulation claims May delay substitution if the approved product depends on a protected formulation
Manufacturing claims Can raise API replication costs but rarely block all generic entry
Oncology method claims May support indication-specific exclusivity
Transplantation method claims Relevant to specialty use but may be difficult to enforce
Combination claims Can protect use with chemotherapy or immunosuppression

No Orange Book patent dispute or Paragraph IV challenge is established for reparixin because the product has not been approved and listed. Generic companies could challenge relevant patents only after an NDA or other qualifying regulatory pathway creates a commercial reference product.

Has reparixin faced Paragraph IV litigation?

No established Paragraph IV litigation is publicly associated with reparixin. Paragraph IV certification applies to an Abbreviated New Drug Application referencing an approved listed drug. Reparixin has no approved FDA reference product and therefore has no known US Paragraph IV litigation framework.

If reparixin were approved in the future, the litigation profile would depend on the patents listed in the Orange Book. A generic applicant could challenge listed patents through Paragraph IV certification, while a branded sponsor could file suit within the statutory litigation period and obtain the applicable automatic stay.

What is the litigation and settlement status of reparixin?

No major public patent litigation or generic settlement involving reparixin is established in the available development record. There is no known reverse-payment settlement, authorized-generic agreement, or license settlement tied to an FDA-approved reparixin product.

The absence of litigation does not establish freedom to operate. It indicates that the product has not reached the commercial stage at which generic entry disputes usually arise.

How strong is the reparixin patent estate?

The estate appears commercially unproven rather than clearly weak or strong. Patent strength depends on whether enforceable composition claims remain in force in the principal markets.

A practical strength assessment is:

Factor Current assessment
Approved-product protection None established
Orange Book leverage None
Paragraph IV exposure None currently established
Composition-of-matter value Potentially high if surviving claims remain broad
Method-of-use value Moderate to low unless tied to a defined biomarker or approved indication
Formulation value Unknown
Manufacturing barriers Potentially relevant but unlikely to prevent all competition
Litigation record No material public record identified
Commercial certainty Low because clinical and regulatory milestones remain incomplete

The most important question is whether a future product would be protected by an unexpired compound patent or only by narrower use and formulation claims. The latter would produce a shorter and more vulnerable exclusivity period.

What are reparixin’s licensing and ownership arrangements?

Dompé Farmaceutici is the principal company associated with reparixin development. Public company materials and clinical-trial records identify Dompé as the sponsor or developer in key studies.[1,2]

No large, publicly disclosed commercialization transaction comparable to major oncology licensing deals is established for reparixin. The lack of a disclosed global licensing transaction suggests that rights may remain concentrated with the originator or have been handled through limited regional arrangements.

Any future partnership would likely require a licensee with:

  • Oncology development capability.
  • Regulatory infrastructure in the US, Europe, and Asia.
  • Access to breast-cancer trial networks.
  • A strategy for specialty transplantation or inflammatory disease.
  • Willingness to fund a new late-stage program.

What is the market opportunity for reparixin?

The market opportunity differs sharply by indication.

Oncology market

Breast cancer is the only indication with a plausible large commercial market. Global breast-cancer drug spending is substantial, but reparixin would not capture the entire market. Its realistic market would be limited to a biomarker-defined or treatment-line population.

A commercial oncology product would need to show one of the following:

  • Improved overall survival.
  • Durable progression-free survival.
  • Reduced recurrence in a high-risk population.
  • Improved response to chemotherapy.
  • Benefit in a population with limited treatment options.

A new breast-cancer therapy entering the market today would face established products from AstraZeneca, Daiichi Sankyo, Roche, Novartis, Pfizer, Merck, and others. The competitive bar is high, particularly in HER2-positive, hormone-receptor-positive, and triple-negative breast cancer.

Islet-transplant market

The islet-transplant market is small but could support premium pricing if reparixin improves graft durability or reduces the need for repeated transplantation. The US patient population is limited, and treatment is concentrated in specialist centers.

This opportunity is more likely to support an orphan or specialty-product strategy than a conventional primary-care commercial model.

Inflammatory and pulmonary markets

Broad inflammatory indications could create larger patient populations, but they also create more competition from corticosteroids, biologics, JAK inhibitors, and other immunomodulators. Safety would be critical because CXCR1/CXCR2 inhibition can affect host defense and neutrophil biology.

What could reparixin sales look like?

A scenario-based projection is more appropriate than a point forecast because reparixin has no approved label or confirmed launch date.

Scenario Commercial path Indicative peak annual sales
No further development Program discontinued or remains inactive $0
Specialty transplantation launch Narrow approval with premium pricing $25 million-$100 million
Limited oncology approval Biomarker-defined breast-cancer use $100 million-$300 million
Successful broad oncology positioning Demonstrated benefit in a sizeable breast-cancer segment $300 million-$750 million
Multi-indication success Oncology plus transplantation or inflammatory disease Above $750 million, low probability

These ranges are strategic estimates, not company guidance. They assume successful regulatory approval, commercial manufacturing, payer access, and clinical differentiation. The probability-weighted value is materially lower because reparixin has not demonstrated a public late-stage regulatory path.

The most probable commercial outcome is continued development inactivity or a narrow specialty indication unless new clinical data materially improve the efficacy case.

What generic launch risks exist for reparixin?

If reparixin reaches approval, generic-entry risk would be moderate to high over the long term. The risk profile would depend on the final product:

  • A simple oral tablet would generally be easier to reproduce than a complex delivery system.
  • A broad compound patent could delay generic entry.
  • A formulation patent would have limited value if a generic can design around it.
  • Method-of-use patents would be vulnerable if physicians prescribe generics for non-protected indications.
  • Manufacturing patents could increase cost but may not prevent alternative synthesis routes.

The absence of an established Orange Book listing means no current generic launch date can be calculated.

How does reparixin compare with competing drug classes?

Drug class Primary use in breast cancer or inflammation Competitive position versus reparixin
Antibody-drug conjugates Targeted cytotoxic delivery Strong clinical and commercial incumbency in advanced breast cancer
Immune checkpoint inhibitors Immunotherapy in selected breast cancers Established regulatory pathways and biomarker strategies
PARP inhibitors BRCA-mutated disease Defined molecularly selected population
CDK4/6 inhibitors HR-positive breast cancer Large evidence base and broad adoption
Corticosteroids Broad inflammatory control Low cost and extensive clinical familiarity
CXCR2 inhibitors Neutrophil and tumor-microenvironment modulation Mechanistically related competition, limited approved precedent
Reparixin CXCR1/CXCR2 inhibition Differentiation depends on clinical proof and patient selection

Reparixin would need a clear biomarker or treatment advantage. Mechanism alone is unlikely to support premium positioning.

What are the main development risks?

The principal risks are clinical translation, regulatory uncertainty, and commercial competition.

Clinical risk is highest in oncology because early mechanistic findings may not produce durable patient benefit. Safety risk relates to infection susceptibility, neutrophil function, liver effects, and interactions with chemotherapy or immunosuppression. Regulatory risk is high because no established approval precedent exists for reparixin.

Manufacturing risk is lower than for a biologic because reparixin is a small molecule. The product would not face cold-chain complexity typical of monoclonal antibodies, but API supply, polymorphism, formulation stability, and GMP scale-up would still require validation.

Key Takeaways

  • Reparixin is an investigational oral CXCR1/CXCR2 inhibitor associated primarily with Dompé Farmaceutici.
  • It has been studied in breast cancer, pancreatic islet transplantation, and inflammatory conditions.
  • Reparixin is not FDA-approved and has no confirmed US launch or exclusivity expiration date.
  • No Orange Book listing, Paragraph IV challenge, major generic litigation, or settlement is established.
  • Breast cancer offers the largest potential market but also presents the highest competitive and clinical-development barriers.
  • Islet transplantation could support a smaller specialty market if graft-survival benefits are proven.
  • Indicative peak sales range from $25 million in a narrow specialty scenario to $300 million-$750 million in a successful oncology scenario.
  • The current probability-weighted commercial value remains low without new positive mid- or late-stage data.

FAQs

Is reparixin available by prescription?

No. Reparixin is an investigational drug and is not approved for routine prescription use.

Is reparixin a biologic or a small-molecule drug?

Reparixin is a small-molecule drug. It would follow the conventional NDA pathway in the United States rather than the biosimilar pathway.

Does reparixin have an approved breast-cancer indication?

No. Clinical studies have evaluated reparixin in breast cancer, but no approved breast-cancer indication has been established.

Could reparixin qualify for orphan-drug status?

Potentially, depending on the selected indication and disease prevalence. Pancreatic islet transplantation or a narrowly defined inflammatory condition could offer a stronger orphan-designation case than broad breast cancer.

What would most improve reparixin’s commercial outlook?

A randomized study showing a durable and clinically meaningful benefit in a defined breast-cancer subgroup would have the greatest effect on the asset’s value. A validated biomarker, regulatory alignment, and a defensible composition or formulation patent would further improve its commercial position.

References

  1. ClinicalTrials.gov. (n.d.). Search results for reparixin clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=reparixin

  2. Dompé Farmaceutici S.p.A. (n.d.). Reparixin development information. Dompé. https://www.dompe.com/

  3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

  5. National Cancer Institute. (n.d.). Breast cancer treatment. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.